Log in  First Connection?

Kidney TransplantationArchives

First robot-assisted radical prostatectomy using Hugo™ robotic-assisted surgery system in a post-kidney transplant patient: a case report

 Published on 26/11/2025 |  Original article (Full-text)  | Fukuda Miruzato et al. | Journal of Medical Case Reports 2025; 19(1): 594

Robot-assisted surgery has attracted significant interest because of its precise and minimally invasive nature. Hugo™ robotic-assisted surgery (RAS) system was introduced by Medtronic in 2021 (Medtronic Ltd, Fridley, MN), and it represents a technological advancement featuring independently mounted...

Impact of delayed graft function on overall and graft survival in recipients of deceased donor kidney transplants

 Published on 19/11/2025 |  Original article (Full-text)  | Negret María et al. | BMC Nephrology 2025; 26(1): 633

In renal transplantation, delayed graft function (DGF) is mainly defined as needing dialysis within the first week after the transplant. This condition is primarily due to ischemia‒reperfusion injury, which involves microvascular inflammation, cell death, and apoptosis and can be influenced by...

The use of terlipressin to treat refractory hypotension during allograft kidney transplantation: a report of 4 cases and literature review

 Published on 12/11/2025 |  Original article (Full-text)  | Yang Wen-He et al. | BMC Anesthesiology 2025; 25(1): 549

Kidney transplantation is a treatment most frequently used for patients suffering from end-stage renal disease (ESRD) which may provide the best opportunity for long-term and dialysis-free survival [1]. However, intraoperative hypotension often occurs in the post-anastomosis reperfusion stage, which...

Rituximab in antibody-mediated rejection following kidney transplantation: clinical and pathological outcomes

 Published on 05/11/2025 |  Original article (Full-text)  | Yilmaz Banu et al. | BMC Nephrology 2025; 26(1): 600

The primary therapeutic in the management of acute antibody-mediated rejection (AMR) are to diminish pathogenic donor-specific antibody (DSA) titers, eradicate the clonal B cell or plasma cell populations responsible for their synthesis, inhibit complement activation, mitigate endothelial injury, and...